vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and CareTrust REIT, Inc. (CTRE). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $134.9M, roughly 1.4× CareTrust REIT, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 55.1%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 46.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
AXSM vs CTRE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $134.9M |
| Net Profit | — | $111.3M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | — |
| Net Margin | — | 82.5% |
| Revenue YoY | 57.4% | 55.1% |
| Net Profit YoY | — | 113.5% |
| EPS (diluted) | — | $0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $134.9M | ||
| Q3 25 | $171.0M | $132.4M | ||
| Q2 25 | $150.0M | $112.5M | ||
| Q1 25 | $121.5M | $96.6M | ||
| Q4 24 | $118.8M | $86.9M | ||
| Q3 24 | $104.8M | $77.4M | ||
| Q2 24 | $87.2M | $68.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $111.3M | ||
| Q3 25 | $-47.2M | $74.9M | ||
| Q2 25 | $-48.0M | $68.5M | ||
| Q1 25 | $-59.4M | $65.8M | ||
| Q4 24 | $-74.9M | $52.1M | ||
| Q3 24 | $-64.6M | $33.4M | ||
| Q2 24 | $-79.3M | $10.8M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | 58.1% | ||
| Q2 25 | -24.5% | 61.3% | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | 43.0% | ||
| Q2 24 | -89.5% | 15.1% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | 82.5% | ||
| Q3 25 | -27.6% | 56.6% | ||
| Q2 25 | -32.0% | 60.9% | ||
| Q1 25 | -48.9% | 68.1% | ||
| Q4 24 | -63.1% | 60.0% | ||
| Q3 24 | -61.7% | 43.2% | ||
| Q2 24 | -91.0% | 15.6% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $0.52 | ||
| Q3 25 | $-0.94 | $0.35 | ||
| Q2 25 | $-0.97 | $0.35 | ||
| Q1 25 | $-1.22 | $0.35 | ||
| Q4 24 | $-1.54 | $0.30 | ||
| Q3 24 | $-1.34 | $0.21 | ||
| Q2 24 | $-1.67 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $198.0M |
| Total DebtLower is stronger | $70.0M | $894.2M |
| Stockholders' EquityBook value | — | $4.0B |
| Total Assets | $713.6M | $5.1B |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $198.0M | ||
| Q3 25 | $325.3M | $712.5M | ||
| Q2 25 | $303.0M | $306.1M | ||
| Q1 25 | $300.9M | $26.5M | ||
| Q4 24 | $315.4M | $213.8M | ||
| Q3 24 | $327.3M | $377.1M | ||
| Q2 24 | $315.7M | $495.1M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $894.2M | ||
| Q3 25 | — | $893.8M | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $822.1M | ||
| Q4 24 | — | $396.9M | ||
| Q3 24 | — | $396.7M | ||
| Q2 24 | — | $671.1M |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $4.0B | ||
| Q3 25 | $73.7M | $4.0B | ||
| Q2 25 | $73.1M | $3.3B | ||
| Q1 25 | $53.2M | $2.9B | ||
| Q4 24 | $57.0M | $2.9B | ||
| Q3 24 | $92.9M | $2.4B | ||
| Q2 24 | $102.9M | $1.9B |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $5.1B | ||
| Q3 25 | $669.3M | $5.1B | ||
| Q2 25 | $639.8M | $4.7B | ||
| Q1 25 | $596.7M | $3.9B | ||
| Q4 24 | $568.5M | $3.4B | ||
| Q3 24 | $561.5M | $2.9B | ||
| Q2 24 | $548.2M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $394.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.54× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $394.0M | ||
| Q3 25 | $1.0M | $100.9M | ||
| Q2 25 | $-32.4M | $100.8M | ||
| Q1 25 | $-43.4M | $71.4M | ||
| Q4 24 | $-26.2M | $244.3M | ||
| Q3 24 | $-18.6M | $67.2M | ||
| Q2 24 | $-30.1M | $53.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.54× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 1.47× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | — | 4.68× | ||
| Q3 24 | — | 2.01× | ||
| Q2 24 | — | 4.92× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
CTRE
Segment breakdown not available.
